Physician profile
Nathan Campbell
NPI 1356799290
$3,962.75
in general payments reported to CMS, 2019-2025
24 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2022: $413 · 2023: $688 · 2024: $522 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,051 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,051.01 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.18 | 2022-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $408.08 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $378.81 | 2022-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $323.17 | 2023-2025 | Omvoh |
| Pfizer INC. | $242.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.92 | 2022-2025 | Entyvio, Gattex |
| Boston Scientific Corporation | $134.33 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $130.63 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.44 | 2025 | Xifaxan |
| Allergan, INC. | $117.04 | 2019 | |
| Aimmune Therapeutics, INC. | $115.55 | 2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $111.76 | 2024-2025 | |
| Braintree Laboratories, INC. | $93.10 | 2022-2025 | Suflave, Sutab |
| Genzyme Corporation | $84.05 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.72 | 2019-2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $69.28 | 2025 | Rezdiffra |
| Celltrion USA INC. | $55.56 | 2025 | Vegzelma |
| Olympus America INC. | $50.72 | 2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope, Evis Exera III Video System Center |
| Phathom Pharmaceuticals, INC. | $45.27 | 2025 | Voquezna |
| Ardelyx, INC. | $31.78 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $30.93 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $24.85 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $24.04 | 2023 | Dificid |
| Amgen INC. | $18.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.